Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed July 2026
Key Takeaways
- Acoramidis is a transthyretin stabilizer indicated for wild-type or variant ATTR-CM in adults.
- The labeled dose is 712 mg twice daily, and the pivotal clinical trial included long-term treatment exposure, supporting assessment of sustained clinical outcomes.
- The clinical benefit of acoramidis is best characterized as targeted TTR stabilization and cardiovascular event reduction, not reversal of established myocardial amyloid.
- Gastrointestinal tolerability and an early, reversible renal laboratory shift are the safety considerations described in the prescribing information.
What Acoramidis Is and How It Works
Acoramidis is a selective transthyretin stabilizer indicated for the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis in adults. The labeled dose is 712 mg orally twice daily, and the drug acts by binding transthyretin and slowing tetramer dissociation, the rate-limiting step in amyloid formation. This mechanism explains why acoramidis slows disease progression rather than reversing established amyloid deposition. It places acoramidis within the ATTR-CM treatment landscape alongside tafamidis as an approved transthyretin stabilizer.
Key Safety Findings
The safety experience comes from a randomized, placebo-controlled trial with a 30-month treatment duration. Gastrointestinal reactions were more common with acoramidis than placebo, including diarrhea reported in 11.6% versus 7.6% and upper abdominal pain in 5.5% versus 1.4%. An early renal laboratory shift also appears: a mean decrease in eGFR of 8.2 mL/min/1.73 m2 was observed at Day 28 and then stabilized, with reversibility after discontinuation. These findings should be considered during patient counseling and routine monitoring but don’t indicate reversal of established cardiac damage.
The labeled dose and main safety signals are summarized below.
| Parameter | Acoramidis | Placebo |
|---|---|---|
| Labeled dose | 712 mg (two 356-mg tablets) twice daily | \- |
| Diarrhea | 11.6% | 7.6% |
| Upper abdominal pain | 5.5% | 1.4% |
| Day-28 mean eGFR change | Decrease of 8.2 mL/min/1.73 m2 (reversible, then stabilized) | \- |
Clinical Benefit Reflects Disease Stabilization Rather Than Reversal
An exploratory ATTRibute-CM analysis provides additional evidence on recurrent and cumulative cardiovascular outcomes, supporting a sustained clinical benefit over time. Overall, the available evidence supports describing acoramidis as a disease-modifying therapy that slows disease progression rather than reverses established myocardial damage. Additional evidence, including its limits, is discussed in acoramidis evidence in ATTR-CM and its role in treatment sequencing in acoramidis sequencing.
Clinical Decision Point
Acoramidis is most appropriately used as a disease-modifying treatment in confirmed ATTR-CM, with realistic expectations set at slowed progression and event reduction rather than reversal. The practical decisions are tolerability counseling for gastrointestinal effects, awareness that the early eGFR change is expected and reversible, and a plan for sustained exposure, especially since a stabilizer expresses its benefit long term rather than immediately after treatment initiation.
Frequently Asked Questions
Does acoramidis reverse ATTR-CM?
No. Acoramidis binds transthyretin and slows new amyloid formation; it doesn’t clear established deposits or reverse fixed structural damage. The appropriate clinical expectation is targeted stabilization, not reversal.
What is the labeled acoramidis dose?
The labeled dose is 712 mg orally twice daily, taken as 356 mg tablets, with or without food.
What are the main safety signals?
Gastrointestinal effects, such as diarrhea and upper abdominal pain, were more common than with placebo, and an early mean decrease in eGFR occurred at Day 28 that stabilized and was reversible after discontinuation.
Is acoramidis better than tafamidis?
No head-to-head trial establishes superiority between the two stabilizers. Therefore, no superiority claim can be made for either agent. Treatment selection should be based on individual patient factors, including phenotype, tolerability, access, and treatment persistence.
Part of the Spotlight On ATTR-CM resource center.
References:
- ATTRUBY (acoramidis) prescribing information. U.S. Food and Drug Administration
- Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. PubMed
- Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. PubMed
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.